Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Regulus Therapeutics Stories

2013-09-09 08:26:40

--Biogen Idec and Isis to leverage antisense technology to accelerate discovery and development of novel therapies-- WESTON, Mass. and CARLSBAD, Calif., Sept. 9, 2013 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's expertise in neurology with Isis'...

2013-08-13 16:26:17

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End - LA JOLLA, Calif., Aug. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended June 30, 2013 and provided a summary of recent corporate highlights. "The second...

2013-08-06 16:28:39

LA JOLLA, Calif., Aug. 6, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2013 on Tuesday, August 13, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, August 13, 2013 at 5:00 pm Eastern Daylight Time to...

2013-07-29 20:20:57

CARLSBAD, Calif., July 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2013 Financial Results and Highlights Conference Call When: Tuesday, August 6, 2013 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How:...

2013-07-23 08:30:40

LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the completion of an underwritten public offering of 5,175,000 shares of common stock, including 675,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a price to the public of $9.50 per...

2013-07-17 08:26:03

LA JOLLA, Calif., July 17, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of a public offering of 4,500,000 shares of its common stock at a price of $9.50 per share. The gross proceeds to Regulus from this offering are expected to be approximately $42.8 million, before deducting underwriting discounts and commissions and estimated...

2013-06-11 08:30:59

LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors effective immediately. Dr. Papadopoulos assumes the role of Chairman of the Board from John Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who has been...

2013-05-21 16:27:26

LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT. The conference is being held at the Westin Boston...

2013-05-07 16:29:08

LA JOLLA, Calif., May 7, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2013 on Tuesday, May 14, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, May 14, 2013 at 5:00 pm Eastern Daylight Time to discuss its...

2013-05-02 12:29:32

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2013 Financial Results and Highlights Conference Call When: Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30 p.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web site listed above. If you are unable to participate during the live...